United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,710,500.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00.

United Therapeutics Stock Down 1.7 %

Shares of NASDAQ:UTHR opened at $361.10 on Friday. The firm has a fifty day moving average of $362.68 and a two-hundred day moving average of $360.19. The firm has a market capitalization of $16.12 billion, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $214.75 and a 12-month high of $417.82.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Signaturefd LLC boosted its stake in shares of United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 30 shares during the period. Parallel Advisors LLC boosted its stake in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC boosted its stake in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after buying an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after purchasing an additional 33 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.